SCHEMBL4189064

SCHEMBL4189064

CCCCOCCCNC(=O)c1cccnc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.64
MEN1 O00255 4/20 0.62
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
GAA P10253 2/20 0.60
MAPT P10636 1/20 0.60
HDAC3 O15379 1/20 0.60
HDAC1 Q13547 1/20 0.60
HDAC2 Q92769 1/20 0.60
RAB9A P51151 1/20 0.60
TDP1 Q9NUW8 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
EPHX2 P34913 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.56
CYP2C9 P11712 1/20 0.56
ALOX15 P16050 1/20 0.56
CYP2C19 P33261 1/20 0.56
HSD17B10 Q99714 1/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4189041 0.91 KMT2A (0.64) KMT2AMEN1CYP1A2CYP3A4GAA
SCHEMBL3241002 0.89 HDAC3 (0.74) KMT2AMEN1CYP1A2CYP3A4MAPT
SCHEMBL29708225 0.89 HDAC3 (0.74) KMT2AMEN1CYP1A2CYP3A4MAPT
SCHEMBL2128698 0.88 HDAC3 (0.68) KMT2AMEN1CYP1A2CYP3A4HDAC3
SCHEMBL16448998 0.86 KMT2A (0.69) KMT2AMEN1CYP1A2CYP3A4MAPT
SCHEMBL25330125 0.86 NAAA (0.68) KMT2AMEN1CYP1A2CYP3A4HDAC3
SCHEMBL2356495 0.86 NAAA (0.68) KMT2AMEN1CYP1A2CYP3A4HDAC3
SCHEMBL9763677 0.86 NAAA (0.68) KMT2AMEN1CYP1A2CYP3A4HDAC3
SCHEMBL11083072 0.86 NAAA (0.68) KMT2AMEN1CYP1A2CYP3A4HDAC3
SCHEMBL2868723 0.86 NAAA (0.68) KMT2AMEN1CYP1A2CYP3A4HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US disclosed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents NAMPT, NNT, NNMT KMT2A 3998/4885MEN1 1428/4885CYP1A2 1889/4885
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS NAMPT, NNT, NNMT KMT2A 3998/4885MEN1 1428/4885CYP1A2 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.